Combined treatment using adenoviral (Ad)-directed enzyme/ prodrug therapy and radiation therapy has the potential to become a powerful method of cancer therapy. We have developed an Ad vector encoding a mutant bacterial cytosine deaminase (bCD) gene (AdbCD-D314A), which has a higher affinity for cytosine than wild-type bCD (bCDwt). The purpose of this study was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of the combination of AdbCD-D314A with the prodrug 5-fluorocytosine (5-FC) and ionizing radiation against human glioma. The present study demonstrates that AdbCD-D314A infection resulted in increased 5-FC-mediated cell killing, compared with AdbCDwt. Furthermore, a significant increase in cytotoxicity following AdbCD-D314A and radiation treatment of glioma cells in vitro was demonstrated as compared to AdbCDwt. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A/5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt/5-FC plus radiation. The results suggest that the combination of AdbCD-D314A/5-FC with radiation produces markedly increased cytotoxic effects in cancer cells in vitro and in vivo. These data indicate that combined treatment with this novel mutant enzyme/prodrug therapy and radiotherapy provides a promising approach for cancer therapy.
Introduction
Glioblastoma multiforme is the most common and highly lethal primary neoplasm of the central nervous system. Treatment generally consists of surgery and radiation therapy in combination with temozolomide. Despite advances in the treatment of malignant glioma, the prognosis remains very poor. Thus, the development of more effective alternative treatments will be critical to improve the survival of patients with these tumors. Among these approaches, molecular chemotherapy/ gene-directed enzyme-prodrug therapy (GDEPT) has received considerable attention. 1 Suicide gene therapy involves delivery of a specific enzyme that can produce cell death through the conversion of an inactive non-toxic prodrug into a cytotoxic drug metabolite. The key element of a GDEPT system is a gene that encodes an enzyme, which converts a prodrug to an active cytotoxic drug. Importantly, prodrug-activating enzymes are normally absent or poorly expressed in mammalian cells. This means tumor-targeting of gene therapy, using specific delivery vehicles, restricts enzyme expression to the transduced tumor cells and adjacent surrounding tumor cells through diffusion of the drug metabolite to generate a bystander effect. One of the most widely used suicide gene/prodrug systems for cancer utilizes cytosine deaminase (CD; EC 3.5.4.1) in combination with the anti-fungal agent 5-fluorocytosine (5-FC) that has been investigated intensely during the last decade. 2 CD is a bacterial or yeast enzyme that can convert 5-FC into the chemotherapy agent 5-fluorouracil (5-FU) which is further processed by cellular enzymes into either 5-fluorouracil triphosphate (5-FUTP) or 5-fluoro-2 0 -deoxyuridine 5 0 -monophosphate . 5-FUTP is incorporated into RNA and interferes with RNA processing, while 5-FdUMP irreversibly inhibits thymidylate synthase and hence DNA synthesis. Importantly, 5-FU is able to diffuse across the cell membrane into adjacent cells without passing through gap junctions, resulting in a more powerful bystander effect. 3 Moreover, 5-FU is a strong radiosensitizer. 4 In the central nervous system, the vast majority of non-malignant cells are non-replicating and terminally differentiated, suggesting that gene therapy for glioma effecting termination of DNA synthesis would be tumor cell-specific. Adenoviral (Ad)-mediated CD gene therapy have been widely studied for glioma treatment in vitro and in animal tumor models. [5] [6] [7] [8] [9] A major problem associated with this suicide GDEPT approach is the low affinity displayed by the CD gene product toward 5-FC in comparison with cytosine. Thus, high doses of this prodrug must be administered in order to achieve cell killing. The plasma levels of 5-FC required to obtain a significant amount of active metabolites may lead to adverse effects. This is observed with 5-FC, whereas deamination by CD of bacterial intestinal microflora into 5-FU is responsible for side effects. 10 Fortunately, recent studies have demonstrated that substitution of an alanine (A) for the aspartic acid (D) at position 314 of bacterial cytosine deaminase (bCD) increased relative specificity of the mutant bCD-D314A enzyme to 5-FC in comparison with wild-type bCD (bCDwt) and may be a superior suicide gene. 11, 12 The aim of this study was to investigate whether Admediated bCD-D314A suicide gene and 5-FC prodrug therapy produces increased cytotoxicity against human glioma cells alone and in combination with radiation therapy. In vivo studies using human glioma xenografts in nude mice examined the therapeutic efficacy of mutant bCD/5-FC therapy alone or in combination with ionizing radiation treatment. The results demonstrated that mutant bCD-D314A Ad-mediated expression was able to significantly enhance CD/5-FC-mediated cytotoxicity of glioma cells and increase antitumor efficacy in human glioma xenograft models in vivo compared to bCDwt.
Results

5-FU sensitivity of human glioma cells
To determine the sensitivity of glioma cell lines to 5-FU, cells were treated with increasing concentrations of 5-FU, and the cytotoxicity of this drug was determined by measuring surviving cells using the crystal violet staining method. The susceptibility to cytotoxic effects of 5-FU was variable in different glioma cell lines. The concentration of 5-FU to produce 50% viable cells (IC 50 , 50% inhibitory concentration) was 3.970.8 mg/ml for D54MG cells, 2.571.2 mg/ml for U251MG cells and 0.970.5 mg/ml for U87MG cells.
Enzyme activity of bCDwt and bCD-D314A in vitro
We constructed the replication-defective recombinant Ad vectors AdbCDwt and AdbCD-D314A, encoding wildtype codA and mutant codA (harboring substitution of an alanine for the aspartic acid at position 314 in the CD protein) genes, respectively, under control of the cytomegalovirus (CMV) promoter. In order to determine the CD conversion activity, human glioma cells were infected with AdbCD-D314A or AdbCDwt, and the enzyme activity was determined by measuring the conversion of 3 H-5-FC to 3 H-5-FU. The results of CD conversion assays demonstrated that the enzyme activity was elevated 183-, 206-and 101-fold for D54MG, U87MG and U251MG cells infected with 2 multiplicity of infection (MOI) of AdbCD-D314A compared to 2 MOI AdbCDwt, respectively. Enzyme activity was enhanced 48-, 69-and 12-fold for D54MG, U87MG and U251MG cells infected with 50 MOI of AdCD-D314A, respectively, in comparison with the levels of enzyme activity in AdbCDwt-infected cells ( Table 1 ). In addition, ionizing radiation at 2 Gy produced enhanced CD conversion of 1.6-and 1.8-fold for D54MG cells infected with 20 MOI of AdbCD-D314A and AdbCDwt, respectively, in comparison with the level of enzyme activity in mock-irradiated cells ( Table 2) . Abbreviations: Ad, adenovirus; bCDwt, wild-type bacterial cytosine deaminase; CD, cytosine deaminase; MOI, multiplicity of infection. a CD activity was determined by measuring the conversion of 3 H-5-FC to 3 To determine the 5-FC sensitivity of tumor cells to Admediated suicide gene expression, human glioma cells were infected with 10 MOI AdbCDwt or AdbCD-D314A and treated with increasing concentrations of 5-FC, and the relative cell viability was determined using the crystal violet staining assay. IC 50 values for glioma cells are shown in Table 3 . Expression of the mutant bCD protein in glioma cells significantly increased their sensitivity to 5-FC treatment. The IC 50 with 5-FC administration decreased by 7.8-fold for D54MG, 32.9fold for U87MG and 8.1-fold for U251MG in AdbCD-D341A-infected cells in comparison with AdbCDwtinfected cells. The viability of AdbCD-D314A-infected cells incubated with 5-FC decreased in an MOI-dependent manner (data not shown).
Combined treatment with AdbCD-D314A/5-FC and ionizing radiation enhanced glioma cytotoxicity
To investigate whether combined treatment with AdbCD-D314A/5-FC and radiation treatment produces increased cytotoxicity of cancer cells in vitro, D54MG glioma cells were first infected with AdbCD-D314A or AdbCDwt at 10 MOI. As shown in Table 4 , the combination of AdbCD-D314A infection and 2 Gy radiation treatment 1 day later produced significant enhanced cell death in comparison with AdbCD-D314A and 5-FC treatment (Po0.05). In contrast, the comparisons of IC 50 values for groups treated with AdbCD-D314A/5-FC 1 day after radiation treatment or on the same day versus the AdbCD-D314A/5-FC-treated D54MG cells showed no significant differences between the groups (P40.05). A similar increase in cell killing following combined treatment with AdbCD-D314A/ 5-FC and ionizing radiation 1 day after infection was obtained with U87MG and U251MG cells (data not shown). In each instance, the 5-FC IC 50 value was substantially lower in AdbCD-D314A as compared to AdbCDwt-infected cells.
To test whether gene therapy using AdbCD-D314A/ 5-FC was able to modulate long-term cell survival in combination with radiation treatment, D54MG glioma cells were infected with 50 MOI AdbCD-D314A or AdbCDwt, exposed to ionizing radiation at 2 Gy and survival determined using a clonogenic survival assay. AdbCDwt-infected D54MG cells demonstrated a reduction in the number of cell colonies to 86% after 2 Gy, 62% after incubation with 5-FC at 4 mg/ml and 92% after combination AdbCDwt/5-FC with radiation treatment in comparison with untreated control cells ( Figure 1 ). There was a significantly greater reduction in the number of AdbCD-D314A-infected D54MG cell colonies to 7.5% after incubation with 5-FC and 0.28% after combined treatment with AdbCD-D314A/5-FC and radiation in comparison with AdbCD-D314Ainfected cells. Also, treatment with AdbCD-D314A/ 5-FC enhanced the radiation-induced U87MG and U251MG glioma cell death, and the cytotoxic effect improved as the MOI of AdbCD-D314A was increased (data not shown). Abbreviations: Ad, adenovirus; 5-FC, 5-fluorocytosine; IC 50 , 50% inhibitory concentration; IR, irradiation; ND, not determined. a D54MG glioma cells were infected with 10 MOI of AdbCD-D314A or AdbCDwt, and mock-irradiated (Ad) or irradiated with 2 Gy using a 60 Co gamma irradiator 1 day before (IR+Ad), concurrently (Ad/IR) or 1 day after Ad infection (Ad+IR). 5-FC cytotoxicity was determined on day 5 after Ad infection by crystal violet staining assay and cell survival was corrected for background absorbance of IR alone control. *Po0.005 for AdbCD-D314A in comparison with AdbCDwt; **Po0.05 for AdbCD-D314A followed by irradiation or AdbCDwt followed by irradiation compared to AdbCD-D314A or AdbCDwt alone, respectively.
Figure 1
Ad-mediated suicide gene therapy increased radiationinduced glioma cell death. Clonogenic survival assay of D54MG glioma cells. Twenty-four hours after infection with 50 MOI of AdbCDwt or AdbCD-D314A, 5-FC was added at 4 mg/ml and the next day cells were either mock-irradiated or irradiated at 2 Gy. Cells were fixed and colonies were counted at 21 days after treatment. Data are presented as percentage of colonies in comparison with mock-irradiated control. Presented are mean7s.d.'s of three independent experiments, each performed in six replicates. *P ¼ 0.003 for AdbCD-D314A in comparison with AdbCDwt plus 5-FC-treated cells; **P ¼ 0.017 for AdbCD-D314A plus 5-FC in combination with radiation treatment in comparison with AdbCD-D314A plus 5-FC alone. Ad, adenovirus; bCD, bacterial cytosine deaminase; bCDwt, wild-type bCD; 5-FC, 5-fluorocytosine; MOI, multiplicity of infection.
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Enzyme activity of bCDwt and bCD-D314A in D54MG glioma xenografts
Taking into consideration the results of previous experiments, D54MG glioma cells were selected for subsequent animal studies of combined suicide gene therapy with radiation treatment because they were the most resistant for in vitro treatment with 5-FU and bCDwt suicide gene therapy, and thus provided the most stringent test of the efficacy of this therapy. The CD enzyme activity was determined by measuring the conversion of 3 H-5-FC to 3 H-5-FU in D54MG glioma xenografts after intratumoral (i.t.) injection with AdbCD-D314A or AdbCDwt ( Figure 2 ). The results of CD conversion assays demonstrated that enzyme activity was elevated 303-fold at 2 days after Ad injection in tumors injected with AdbCD-D314A (40.9 pmol/min/mg) in comparison with AdbCDwt-injected tumors (0.135 pmol/min/mg). Also, combination AdbCD-D314A infection with radiation treatment increased CD enzyme activity in D54MG tumors ( Figure 2 ). At 14 days after infection, there was a significant increase in enzyme activity in D54MG glioma xenografts treated with radiation 1 day after AdbCD-D314A infection (63.0718.5 pmol/min/mg) in comparison with AdbCD-D314A alone (14.1711.4 pmol/min/ mg, P ¼ 0.018). In contrast, there were not significant differences in CD conversion values between D54MG tumors injected with AdbCD-D314A 1 day after irradiation (38.8726.7 pmol/min/mg) versus AdbCD-D314A alone (P ¼ 0.267) and AdbCD-D314A 1 day before versus after irradiation (P ¼ 0.215).
In vivo therapy of D54MG glioma xenografts using suicide gene therapy alone or in combination with radiation treatment Subcutaneous glioma therapy model. To further evaluate the therapeutic potential of combination suicide gene therapy with radiation treatment in vivo, D54MG cells were subcutaneously (s.c.) injected into the flank of athymic nude mice. Before treatment, the mean tumor sizes in groups of 10 mice at baseline were not significantly different between treatment groups (P40.05), and the within treatment variances were not significantly different (P40.05). The baseline mean and standard deviation for tumor sizes at 14 days post tumor cell injection was 70.1718.6 mm 2 . In vivo tumor therapy was initiated on day 0, which corresponded to 14 days post-tumor cell injection. Animals were injected i.t. with 1 Â 10 8 TCID 50 (50% tissue culture infectious dose) AdbCD-D314A or AdbCDwt on days 0, 7 and 14. 5-FC was administered intraperitoneally (i.p.) at 500 mg/kg twice daily 5 days/week for 3 weeks. Three groups of mice received radiation treatment at 2 Gy on days 4, 7 and 10. An inhibition of D54MG tumor growth was noted in groups of mice treated with AdbCD-D314A/ 5-FC alone and AdbCD-D314A/5-FC in combination with radiation treatment versus the 5-FC-injected group (Figure 3 ). There were no significant differences in tumor growth between groups that received 5-FC plus radiation treatment versus 5-FC alone, 5-FC plus radiation versus AdbCDwt/5-FC, or AdbCDwt/5-FC versus AdbCDwt/ 5-FC in combination with radiation treatment (P40.05).
The mean time to tumor doubling for 5-FC alone, 5-FC plus radiation, AdbCDwt/5-FC, AdbCDwt/5-FC plus radiation, AdbCD-D314A/5-FC and AdbCD-D314A/ 5-FC in combination with radiation treatment groups were 13, 15, 16, 17, 38 and 54 days, respectively. Comparisons of mean time to tumor doubling of the group treated with AdbCD-D314A/5-FC in combination with radiation versus AdbCD-D314A/5-FC alone and AdbCD-D314A/ 5-FC versus AdbCDwt/5-FC plus radiation showed significant differences between the groups (Po0.05).
To test whether increased doses of radiation combined with suicide gene therapy of s.c. D54MG glioma xenografts had greater efficacy, athymic nude mice were irradiated with three or six 5 Gy fractions after AdbCD-D314A/5-FC treatment ( Figure 4 ). Before treatment, the mean tumor sizes in groups of 10 mice at baseline were Intracranial glioma therapy model. The potential clinical efficacy of suicide gene therapy using mutant bCD-D314A was assessed in an intracranial athymic nude mouse model of D54MG human glioma. Data from a preliminary study showed that AdbCD-D314A/5-FC treatment prolonged survival of mice bearing intracranial D54MG tumors in comparison with mock-infected animals treated with 5-FC or AdbCD-D314A alone (24 versus 13 days). To test whether the combination of suicide gene therapy with radiation is more effective than either treatment alone, mice bearing intracranial D54MG tumors were irradiated with 5 Gy fractions on days 1, 3 and 7 after a single i.t. injection of AdbCD-D314A on day 0 (6 days post-tumor cell injection), plus a 2-week course of i.p. 5-FC at 500 mg/kg twice daily on days 0-4 and 7-11. As shown in Figure 5 
Discussion
Chemotherapy is widely used with surgery and radiotherapy for the treatment of cancer. Selectivity of most drugs for malignant cells remains elusive. The efficacy of standard chemotherapy tends to be limited by development of resistance to treatment. Unfortunately, an insufficient therapeutic index, a lack of specificity, and the emergence of radiation and drug resistant cell subpopulations often hamper the efficacy of glioma therapy. 13 A major problem for cancer treatment is the presence of toxic side effects associated with chemotherapeutic agents that limit their efficacy. There is a need for the development of new alternative therapeutic strategies. Among these approaches, GDEPT using the CD/ 5-FC system has been developed. In this methodology, the codA gene encoding for the CD enzyme that converts the prodrug 5-FC to 5-FU is delivered to the target tumor cells, resulting in their death. Although this approach has been in development for some time, new combinations with cancer therapies, such as selective conventional chemotherapy and radiotherapy, are being tested. 2, 6, 14, 15 Also, to enhance efficacy of CD/5-FC molecular chemotherapy, several strategies have been developed, including irradiation of the tumor, 6,16-18 use of vectors encoding the bCD:uracil phosphoribosyltransferase fusion gene, 6, 19, 20 or a combination of bCDwt/5-FC and herpes simplex virus thymidine kinase/ganciclovir suicide gene therapy. [21] [22] [23] Since one of the major limitations in current cancer gene therapy is the poor efficacy of in vivo gene transfer, successful application of a suicide gene will depend on its bystander killing effect. In the CD/5-FC system, the bystander effect is caused by the passive diffusion of 5-FU into the extracellular milieu and its diffusion into the adjacent cells, which requires Enzyme/prodrug therapy of glioma SA Kaliberov et al no gap junctions. 24 In another approach, yeast CD (yCD) gene therapy has been developed. Although yCD is more efficient at converting 5-FC into the cytotoxic drug 5-FU than bCDwt, this enzyme loses all activity by 96 h at 371C in contrast to bCD, which retains 100% of its activity at 168 h. This loss of activity could be a critical factor in the therapeutic efficacy in vivo. 25 In the present study, we investigated mutant bCD gene transfer in an Ad-directed molecular chemotherapy approach for treatment of human glioma cells in vitro and in vivo. It was shown previously that the D314A mutation in bCD decreased efficiency for endogenous cytosine, which can compete with prodrug for the active enzyme site in combination with increased efficiency for 5-FC that resulted in 19-fold relative substrate preference for 5-FC in comparison with bCDwt. 11, 12 Thus, the rationale for using the mutant bCD gene was that the bCD mutant D314A would more effectively convert 5-FC to 5-FU and increase the antitumor activity without adverse effects.
As expected, a more potent cytotoxicity effect for human glioma cells was obtained using AdbCD-D314A/ 5-FC treatment in comparison with AdbCDwt/5-FC. A comparative study of AdbCD-D314A/5-FC and AdbCDwt/5-FC showed that increased cytotoxicity of mutant bCD-D314A/5-FC gene therapy correlated with significantly increased CD conversion in AdbCD-D314Atreated cells. The combination of AdbCD-D314A/5-FC suicide gene therapy and radiation treatment 1 day after infection produced moderately increased cytotoxicity in vitro in comparison with these treatments alone and when D54MG cells were irradiated 1 day before or concurrent with Ad infection. However, the results of in vivo experiments demonstrated a significant delay in D54MG glioma tumor growth following AdbCD-D314A/5-FC treatment alone in comparison with AdbCDwt/5-FC alone or in combination with ionizing radiation, and when combined with radiation treatment in comparison with AdbCD-D314A/5-FC alone. These results also were confirmed using the D54MG intracranial model for survival studies. Generally, the relative response of the animal tumor models correlated with the observed in vitro proliferation and conversion assays with D54MG glioma cells. Notably, high levels of CD enzyme activity were observed for 14 days after single i.t. injection of AdbCD-D314A vector into D54MG glioma xenografts. Also, the CD conversion results demonstrated enhanced enzyme activity at 14 days after injection of tumors with AdbCD-D314A in combination with ionizing radiation 1 day before or after infection versus AdbCD-D314A alone (2.8 or 4.5-fold, respectively). These results are consistent with recently published data that irradiation treatment of colon cancer xenografts increased the Ad uptake and Ad-mediated transgene expression in tumor cells in a dose-and timedependent manner 26 and correlated with elevated Dynamin 2 expression. 27 Gene therapy of cancer, in particular suicide gene therapy, has entered several clinic trials, and the factors limiting its efficacy have attracted increasing attention. Thus, target specificity, low in vivo transduction efficacy or limited cytotoxic effects are currently subjects of intense research. 28, 29 The rationale behind suicide gene therapy is that after targeted transfer of these genes into tumor cells, only tumor and neighboring cells will be rendered sensitive to their cytotoxic action. As suicide gene therapy is essentially a tumor-targeted chemotherapy, the systemic toxicity commonly associated with, and a major limitation of, conventional chemotherapy is avoided. Specifically, targeted expression of the prodrugactivating enzyme avoids systemic toxicity, and results in high drug concentrations in the tumor mass and an improved therapeutic index compared to systemic drug administration. Thus, tumor-targeted suicide gene therapy is an attractive approach for human glioma therapy since local gene delivery is feasible. Also, employing a conditionally replicating Ad with selective oncolytic activity should increase therapeutic efficacy of molecular chemotherapy of glioma. 30 The construction of such vectors is under way in our laboratory.
These results indicate that the combination of AdbCD-D314A/5-FC suicide gene therapy with radiation treatment produced increased cytotoxicity in human glioma cells in vitro and in vivo. Combination treatment with ionizing radiation can increase expression of suicide enzymes in glioma cells, and thus produce greater cytotoxicity. In summary, these studies indicate that treatment using mutant CD for suicide gene/5-FC prodrug therapy in combination with radiation treatment provides a promising approach for glioma therapy.
Materials and methods
Tumor cells, animals, chemicals, antibodies and recombinant adenoviruses
Human glioma cell lines D54MG and U251MG (A kind gift from Dr Darell D Bigner, Duke University, Durham, NC, USA) and U87MG (American Type Culture Collection, Manassas, VA, USA), and HEK293 human embryonic kidney cells (Microbix Biosystems, Ontario, Canada) were cultured in Dulbecco's modified Eagle's medium/F12 (Mediatech, Herndon, VA, USA) containing 10% fetal bovine serum (Summit Biotechnology, Fort Collins, CO, USA). All cells were cultured at 371C in a 5% CO 2 atmosphere without antibiotics.
Female nude athymic mice were purchased from the Frederick Cancer Research Facility (Bethesda, MD, USA) and housed under aseptic conditions in microisolator cages and experiments were carried out according to the Institutional Animal Care and Use Committee approved protocols.
5-FC and 5-FU were purchased from Sigma-Aldrich (St Louis, MO, USA) and SP Pharmaceuticals (Albuquerque, NM, USA), respectively.
A replication-deficient E1-and E3-deleted AdbCDwt recombinant Ad vector encoding the wild-type CD enzyme from Escherichia coli (CD; EC 3.5.4.1) gene (codA), under control of the human CMV immediate-early promoter was constructed by two-plasmid rescue in HEK293 cells using pACCMVpLpA shuttle vector and pJM17 rescue vector as described previously. 16 A replication-deficient E1-and E3-deleted AdbCD-D314A recombinant Ad vector encoding the mutant codA gene driven by the CMV promoter was developed using pAdEasy system (Quantum Biotechnologies, Montreal, Canada), as per the manufacturer's protocol. Briefly, to generate pShuttle-bCD-D314A plasmid, the fragment containing bCD-D314A was removed from pETHT:bCD plasmid 11 by restriction digestion, blunted and cloned Enzyme/prodrug therapy of glioma SA Kaliberov et al into a pShuttle-CMV plasmid (Quantum Biotechnologies). The insert sequence and orientation were confirmed by restriction enzyme mapping and partial sequencing analysis. The resultant plasmid was linearized and co-transfected with pAdEasy-1 plasmid (Quantum Biotechnologies) into E. coli BJ5183 bacteria. Recombinant clones were confirmed by polymerase chain reaction (PCR) analysis, linearized and transfected into permissive HEK293 cells using the Effectene lipid-based transfection method (Qiagen, Chatsworth, CA, USA) to generate AdbCD-D314A recombinant Ad, which was isolated from a single positive plaque and passed through three rounds of plaque purification and subsequently confirmed by PCR. Viruses were propagated on HEK293 cells and purified twice by centrifugation on CsCl gradients. The quantity of viral particles was monitored by absorbance of the dissociated virus at A 260 nm. Viral titer was measured by a TCID 50 assay. Briefly, HEK293 cells were plated into 96-well plates at 5 Â 10 3 cells/well, and allowed to adhere overnight. Next day, serial dilutions of the viral stock were added directly to cells. Cells were incubated for 10 days, and cytopathic effect was determined using a crystal violet staining assay. Cell culture medium was removed and surviving cells were then fixed and stained with 2% (w/v) crystal violet (Sigma-Aldrich) in 70% ethanol for 3 h at room temperature. The plates were washed extensively, airdried and the ratio of positive wells with observable cytopathic effect for each viral preparation was determined. The viral titer was calculated by the Karber equation: T ¼ 10 1+D(SÀ0.5) /V, where T is infectious titer in TCID 50 /ml, D is the log 10 of the dilution, S is the log 10 for the initial dilution plus the sum of ratios and V is the volume in ml of the diluted virus used for infection. MOI for subsequent experiments was expressed as TCID 50 per cell.
In vitro cytotoxicity assay using crystal violet staining
To measure the cytotoxicity of 5-FU and 5-FC, glioma cells were plated into 96-well tissue culture plates at 5 Â 10 3 cells/well, and allowed to adhere overnight. Next day, serial dilutions of 5-FU or 5-FC were added directly to cells. Cells were incubated for 5 days, and relative cell density was determined using a crystal violet staining assay. Cell culture medium was removed and surviving cells were then fixed and stained with 2% (w/v) crystal violet (Sigma-Aldrich) in 70% ethanol for 3 h at room temperature. The plates were washed extensively, airdried and optical density was measured at 570 nm using a V Max plate reader (Molecular Devices Corporation, Sunnyvale, CA, USA). Fractional cell survival at each drug concentration was calculated as the ratio of absorbance at 570 nm of cells incubated in the presence versus absence of drug, corrected for background absorbance of media alone. Fractional cell survival data were plotted against drug concentration and IC 50 values extrapolated by piecewise linear regression as the concentration of drug producing a 50% reduction in corrected absorbance. For AdbCD-D314A/5-FC and AdbCDwt/5-FC cytotoxicity experiments, the target cells were plated into 96well tissue culture plates at 5 Â 10 3 cells/well, and allowed to adhere overnight. Twenty-four hours later cells were infected with AdbCD-D314A or AdbCDwt at various MOI. Next day, fresh media supplemented with serial dilutions of 5-FC were added, and 24 h after prodrug treatment, glioma cells were either mockirradiated or irradiated at 89 cGy/min using a 60 Co gamma irradiator (Picker Unit, Cleveland, OH, USA) and 5-FC cytotoxicity (IC 50 ) was determined at 5 days using a crystal violet staining assay.
CD conversion assay in vitro
Human glioma cells were seeded into 25 cm 2 flasks, 24 h before infection. Cells were exposed to AdbCD-D314A and AdbCDwt at various MOI for 2 h, culture media was removed and fresh media was added. Forty-eight hours later, the cells were trypsinized and resuspended in CD lysis buffer (100 mM Tris, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, pH 7.8). Cells were frozen and thawed three times, and after centrifugation the supernatant assayed for protein concentration (Bio-Rad Laboratories, Hercules, CA, USA). To start each reaction, 3 H-5-FC was added. After various time points, the reactions were stopped with the addition of 95% ethanol. 5-FC/5-FU (Pharmacia, Peapack, NJ, USA) standards were added to each tube and the whole sample spotted on flexible plates for thin layer chromatography (Whatman, Clifton, NJ, USA). These were run in butanol:water (86:14) to separate the 3 H-5-FU (top) from the 3 H-5-FC (bottom) spots and all were cut out and put into scintillation fluid, and counted using a 1900 TR Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, IL, USA). To determine the specific activity of samples, 3 H-5-FU formed (pmol) was plotted against time. The slope of the graph (pmol formed per min) was then divided by the amount of protein added to obtain the CD activity (expressed as pmol/min/mg protein).
Clonogenic survival assay
At 24 h after infection with 50 MOI AdbCDwt or AdbCD-D314A, cells were trypsinized and diluted to an appropriate cell density and placed into six-well culture plates and allowed to adhere overnight. Next day, 5-FC were added directly to cells at 4 mg/ml, and after 24 h incubation at 371C cells were either mockirradiated or irradiated at 2 Gy using a 60 Co gamma irradiator (Picker Unit) and were then returned to the incubator and cultured additionally for 21 days. Cells were then fixed with 70% ethanol and stained with 2% (w/v) crystal violet (Sigma-Aldrich). Colonies comprising at least 50 cells were counted. The plating efficiencies were calculated as the number of colonies divided by the number of test cells plated for each data point. Plating efficiencies were referenced back to the mock-irradiated control plating efficiency to determine the surviving fraction for each dose.
In vivo CD conversion and therapy studies CD conversion in tumor xenografts. For in vivo CD conversion assay, 2 Â 10 7 D54MG human glioma cells were injected s.c. into female athymic nude mice. When tumors reached 6-8 mm in diameter, groups of three tumors were injected with 1.5 Â 10 8 TCID 50 of AdbCDwt or AdbCD-D314A, and mock-irradiated or irradiated at 2 Gy 1 day before or after injection using a 60 Co gamma irradiator. Tumors were dissected at different times after Ad injection, and one-third of the tumor was crushed with a mortar and pestle in 100 ml Complete Mini Enzyme/prodrug therapy of glioma SA Kaliberov et al protease inhibitor buffer (Roche Diagnostics, Indianapolis, IN, USA). Tumor tissues were frozen and thawed three times, and after centrifugation the supernatant fluids assayed for protein concentration and tested for CD conversion as described above.
Subcutaneous human glioma xenograft model. To assess antitumor effects on established solid tumors, D54MG glioma cells (2 Â 10 7 ) were injected s.c. into female athymic nude mice. Treatment was started 14 days post-tumor cell injection at the time of established tumor growth (tumors were 6-8 mm in diameter), noted as day 0. Animals were randomly divided into groups receiving different treatments: AdbCDwt plus 5-FC; AdbCD-D314A plus 5-FC; AdbCDwt and 5-FC plus radiation; AdbCD-D314A and 5-FC plus radiation; 5-FC plus radiation; and 5-FC alone as control. Mice were injected i.t. with 1 Â 10 8 TCID 50 per tumor AdbCDwt or AdbCD-D314A on days 0, 7 and 14. 5-FC was administered i.p. at 500 mg/kg twice daily 5 days/week for 3 weeks. Radiation treatment was 2 Gy from a 60 Co gamma irradiator on days 4, 7 and 10. For the next experiment, animals were injected 17 days post-D54MG tumor cell injection (day 0) i.t. with 1 Â 10 8 TCID 50 AdbCD-D314A on days 0, 7 and 14 and irradiated with 5 Gy fractions on days 4, 7 and 10 (15 Gy total) or days 4, 7, 10, 14, 17 and 21 (30 Gy total). Two groups of mice received 5-FC i.p. at 500 mg/kg twice daily 5 days per week for 3 weeks beginning on day 0. Tumor size was monitored twice a week with Vernier calipers. Tumor surface area (length Â width in mm 2 ) was calculated for each group of 10 mice and plotted as a percentage change over time relative to the mean size on day 0 for each group.
Intracranial survival study. D54MG tumors were established intracranially in athymic nude mice as described previously. 31 Briefly, mice were anesthetized by i.p. administration of ketamine (20 mg/ml) and xylazine (0.3 mg/ml) in saline at 0.07 ml/10 g of body weight. A midline scalp incision was made, and a 0.5-mm burr hole was drilled 1.5-2.0 mm to the right of midline and 1 mm anterior to the coronal suture. D54MG cells were injected stereotactically at 0.5 Â 10 6 cells (1 Â 10 8 /ml), using a 250 ml Hamilton syringe with a prepared 30 G needle mounted in a Stoelting stereotaxic apparatus. A plastic sleeve surrounding the needle allowed reproducible injections of tumor cells, saline or Ad to a depth of 2.5 mm. The needles were left in place for 2 min to minimize reflux of the tumor cells along the needle track. The scalp wounds were closed with Tissu-Mend glue to avoid scatter dose from metallic wound clips during radiation treatment. The mice were placed on a heating pad in sterile microisolator polycarbonate cages and allowed to awaken from anesthesia. Tumors were allowed to grow for 6 days before the start of treatment (day 0). Animals were randomly divided into groups receiving different treatments: 3.2 Â 10 7 TCID 50 AdbCD-D314A in 10 ml saline; AdbCD-D314A in combination with radiation; AdbCD-D314A plus 5-FC; AdbCD-D314A plus 5-FC in combination with radiation, i.t. saline followed by i.p. 5-FU and i.t. saline plus 5-FC and radiation. On the day after AdbCD-D314A injection, mice were treated i.p. with either saline or 5-FC twice daily at 500 mg/kg on days 0-4 and 7-11 and monitored daily for survival. Radiation therapy consisted of 15 Gy
